TIDMCREO

Creo Medical Group PLC

08 October 2018

Creo Medical Group plc

("Creo" or the "Company")

Investor Open Event at Chepstow

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that it will hold an Open Event for shareholders and potential investors at the Company's headquarters and manufacturing facility in Chepstow, Wales, from 2.30pm onwards on Wednesday 17 October 2018.

The event will provide an opportunity for shareholders and potential investors to hear the latest Company presentation providing an overview of Company strategy and progress and will allow those attending to meet the Senior Management team, take a tour of the facility and familiarise themselves with the Company's suite of medical devices.

To attend please contact Walbrook PR via creo@walbrookpr.com or call 020 7933 8780.

No new material will be disclosed at the event and the presentation will be made available on the website shortly after: http://investors.creomedical.com/investors/reports-and-presentations/2018

 
 Creo Medical Group plc 
 Richard Rees (CFO)                                               +44 (0)129 160 6005 
 
 Cenkos Securities                                                +44 (0)20 7397 8900 
 Stephen Keys/Mark Connelly (NOMAD) 
 Michael Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                           +44 (0)20 7933 8780 or creo@walbrookpr.com 
 Paul McManus                                                     +44 (0)7980 541 893 
 Helen Cresswell                                                  +44 (0)7841 917 679

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, investors.creomedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAEASESESDPFFF

(END) Dow Jones Newswires

October 08, 2018 02:00 ET (06:00 GMT)

Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Creo Medical Charts.
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Creo Medical Charts.